Understand the source comparison
NAD+ Sirtuins Longevity Genes Activation: Comparison of Precursors
Different NAD+ precursors produce measurably different outcomes depending on dose, timing, and metabolic context. Here's how the three primary precursors compare across key research parameters. | Precursor | Cellular Uptake Mechanism | Peak Plasma NAD+ Increas
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different NAD+ precursors produce measurably different outcomes depending on dose, timing, and metabolic context. Here's how the three primary precursors compare across key research parameters.
- | Precursor | Cellular Uptake Mechanism | Peak Plasma NAD+ Increase | Optimal Dosage Range (Research) | Primary Sirtuin Activated | Documented Side Effects | Professional Assessment ||—|—|—|—|—|—|| Nicotinamide Riboside (NR) | Equilibrative nucleoside transporters → NRK phosphorylation → NMNAT conversion | 40–90% at 2–3 hours | 300–1000mg daily | SIRT1 (nuclear), SIRT3 (mitochondrial) | Mild nausea at >1000mg; generally well-tolerated | Most consistent clinical data; best choice for sustained NAD+ elevation in long-term studies || Nicotinamide Mononucleotide (NMN) | Slc12a8 transporter (contested); may require dephosphorylation to NR first | 50–100% at 1–2 hours | 250–500mg daily | SIRT1, SIRT3, SIRT6 | Flushing in 15% of subjects at >500mg; transient | Faster peak response; ideal for acute intervention studies but limited human data vs NR || Nicotinamide (NAM) | Passive diffusion → salvage pathway via NAMPT enzyme | 20–40% (dose-dependent ceiling) | 100–500mg daily (max before inhibit